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Abstract 
Taking inspiration from the assembly of so-called peptoids (N-alkylglycine oligomers) we present a 
new synthetic methodology whereby N-heterocyclic carbene (NHC) based Pd ligands were 
assembled using a sub-monomer approach and loaded with Pd via solid-phase synthesis. This 
allowed the rapid generation a library of NHC–palladium catalysts that were readily functionalised 
to allow bioconjugation. These catalysts were able to rapidly activate a caged fluorophore and 
‘switch-on’ an anticancer prodrug in 3D cell culture. 
 
Introduction  
Bioorthogonal reactions enable the selective visualisation and manipulation of biological processes 
in living systems and have been widely used in a number of applications.1–4 Transition metal 
mediated bioorthogonal reactions are of particular interest as they enable an array of non-natural 
chemical transformations that can be used to modulate living systems.5, 6 Reactions mediated by 
copper,7, 8 iron,9 gold,10-12 ruthenium,12–16 and iridium17 have all found applications in living systems, 
although palladium is perhaps the most utilised metal in a biological setting.18   
Palladium has gained popularity in bioorthogonal chemistry due its ability to perform catalytic cross-
coupling reactions, enabling the generation of carbon–carbon and carbon–heteroatom bonds under 
mild, biological conditions,19–21 and more recently in vivo.22,23 Palladium catalysts have been used to 
initiate a range of intracellular reactions including dealkylation,24 decaging of propargyloxycarbonyl 
groups,18,24,25  as well as Suzuki–Miyaura cross-couplings.20,26-28 Thus, palladium mediated reactions 
have been used to selectively activate enzymes through deprotection of modified amino acids 
within proteins,21, 29 to synthesise anticancer agents in cellulo from two benign precursors,19 as well 
as activate produgs;20–22,24 however, to date, the majority of the examples have used palladium 
nanoparticles entrapped within a polymeric support,19,20,22–24,26,27,30 simple palladium salts such as 
Pd(OAc)2,31–33 or designed targeted palladium ligands.34 
This is in contrast to the highly active palladium catalysts used in conventional organic synthesis that 
use a variety of stabilising ligands (e.g. phosphines) or N-heterocyclic carbenes (NHC),35, 36 but few 
have been used in a biological setting. Chen used an NHC–Pd catalyst (with imidazolium-based 
ligands bearing hydrophilic quaternary ammonium salts) to mediate the Suzuki–Miyaura coupling 
reaction between a boronic acid functionalised biotin and 4-iodophenylalanine modified cell surface 
proteins, enabling subsequent imaging of the cell surface with fluorescently labelled streptavidin.33 
Recently, we reported a water soluble NHC–Pd catalyst coupled to a cell penetrating peptide, which 
was able to remove a propargyloxycarbonyl group from a pro-fluorophore in cells, thus 
demonstrating the first intracellular application of NHC–Pd chemistry.37 While catalyst loading was 
carried out on the solid-phase, the synthesis of the NHC ligand required multistep synthesis in 
solution, purification, and conjugation to a solid support.  
Here, we report an efficient microwave assisted solid-phase synthesis of a series of biocompatible 
NHC–Pd catalysts and their chemistry in cells. To the best of our knowledge, a solid phase approach 
to the generation of NHC–Pd catalysts has not been reported and, with our approach, these stable 
NHC–Pd catalysts were prepared in good yields with the majority of the catalysts showing good 
activity in a biological setting. 
 
Results and discussion 
A solid-phase synthetic route was developed for the NHC–Pd catalysts by adopting the ‘sub-
monomer’ approach, originally developed by Zuckermann for the synthesis of peptoids (N-alkyl 
glycine oligomers), with sequential acylation and alkylation reactions on a resin.38, 39 The NHC ligand 
chosen here was first reported by Meldal who showed that a resin-bound NHC–Pd complex 
(conjugated to a hydrophobic dipeptide) showed good catalytic efficiency in Suzuki–Miyaura cross-
couplings in water.40 Here, this pyridine-derivatised imidazolium ligand was attached to a range of 
different amino acid spacers, with the aim of providing biocompatibility, aqueous stability, as well 
as a handle for biomolecule conjugation. 
 
Solid-phase synthetic route for the NHC–Pd catalysts 
Fmoc-Ahx-OH was coupled to a 2-chlorotrityl chloride linker on a polystyrene resin (mesh 100–200), 
with subsequent removal of the Fmoc group giving 1, which was acylated with 2-bromoacetic acid 
(2 M in DMF) using DIC as a coupling reagent at 60 °C under μw irradiation for 20 min (Scheme 1). 
The bromide in 2 was substituted by imidazole to give 3, with optimised reaction conditions (ESI, 
Table S1) allowing quantitative N-alkylation via an excess of imidazole (2 M) at 60 °C (μw heating for 
40 min) in anhydrous DMSO with 0.5 M AgNO3. The addition of AgNO3 was required for full 
conversion (based on HPLC analysis, ESI Figure S1). The imidazole in 3 was N-alkylated with 2-
(bromomethyl)pyridine (1 M) to give 4 with >95% conversion using Et3N (1 M) and AgNO3 (0.5 M) 
at 60 °C in anhydrous DMF (for optimisation see ESI Table S2) giving the NHC ligand in >95% purity 
and 65% overall yield over 3 steps (ESI, Figure S2 and S3). Palladium loading of the NHC-ligand 4 on 
solid-phase was carried out as reported by Meldal40 with minor modifications. In brief, the carbene 
was generated on the resin from the imidazolium ion with the phosphazene base 2-tert-butylimino-
2-diethylamino-1,3-dimethylperhydro-1,3,2-diazaphosphorine (BEMP) in anhydrous DMF. 
Pd(COD)Cl2 was added subsequently to generate the NHC–Pd catalyst 5 (Scheme 1), which was 
cleaved off the resin with 30% HFIP in DCM and purified by semi-preparative RP-HPLC. This allowed 
the rapid and efficient generation of >100 mg quantities of the catalyst 5 that could be freely 
stored.‡ 
 
 
Scheme 1. The microwave assisted solid-phase synthesis of NHC–Pd catalyst 5. a) 0.3 M Fmoc-Ahx-OH, 0.5 M DIPEA, anhydrous DCM–DMF (9:1), 1 h; b) 20% 
piperidine in DMF, 2 × 10 min; c) 2 M BrCH2CO2H, 1 M DIC, anhydrous DMF, 20 min, 60 °C, μw; d) 2 M imidazole, 0.5 M AgNO3 in anhydrous DMSO, 40 min, 60 
°C, μw; e) 1 M 2-(bromomethyl)pyridine, 1 M EtN3, 0.5 M AgNO3, anhydrous DMF, 90 min, 60 °C, μw; f) BEMP, anhydrous DMF, N2, 45 min, then Pd(COD)Cl2 
overnight; g) 30% HFIP–DCM, 1h. All conversions were monitored by cleavage of a small sample from the resin and characterisation by HPLC and NMR. As 
drawn, the catalyst is Pd(II) with Y most likely formate (from the HPLC purification buffer). 
 
Synthesis of NHC–Pd catalyst library  
This solid-phase synthesis route was used to generate an NHC–Pd catalyst library (5–12). Using the 
NHC moiety with different amino acid spacers gave a range of both hydrophilic and hydrophobic 
groups to compare the potential effect on catalytic activity, as well as the robustness of the synthetic 
method (Figure 1). The catalysts were synthesised using the 2-chlorotrityl linker, but the 
methodology was also compatible with the Rink-amide linker (ESI, catalyst 13). The ligands for 
catalysts 5–12 were fully characterised using NMR, HPLC, and HRMS, and after palladium loading, 
the catalysts were cleaved off the resin, purified by semi-preparative RP-HPLC, and characterised by 
ESI-MS and HPLC (ESI, Table S3). The purity of the catalysts was confirmed by analytical HPLC (ESI, 
Figure S4 and S5 – the “naked ligands” and the Pd-loaded ligands displayed different retention 
times) and the presence of palladium also established by HRMS (ESI, Figure S6) (the presence of the 
Pd meant that the 1H NMR spectra were highly broadened). These catalysts were stable for two 
weeks at room temperature in ACN/H2O, and ³ 8 weeks at 4 °C. 
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 Figure 1. The NHC–Pd catalysts 5–12 synthesised by the optimised solid-phase synthesis protocol (Scheme 1). As drawn, the catalyst is Pd(II). In the biological experiments 
Y can be exchanged to various species with different coordination/charge states possible. 
 
Screening of catalytic activity 
The fluorogenic probe based on 2,7-dichlorofluorescein (DCF) was used to evaluate the activity of 
the catalysts.41 The profluorophore O-propargylated DCF-1 was converted to the fluorescent 
molecule DCF-2 (λEx/Em 480/520 nm) upon Pd-catalysed cleavage of the propargyl group (Figure 2A). 
Catalyst screening was carried out at 37 °C in PBS and in MCF-7 cell lysate to evaluate catalytic 
activity under biologically relevant conditions. Catalysts 5–12 (0.8 mol%) were incubated with DCF-
1 (10 μM) and the increase in fluorescence measured over 4 h with an additional measurement at 
20 h (ESI, Figure S7). With the exception of 7 and 11, all the catalysts were active in PBS with 8 and 
9 showing comparable activity to 0.8 mol% Pd(OAc)2 (Figure 2B). The decaging reactions were 
notably slower in cell lysate with 8 and 9 again showing the best catalytic efficiency under these 
conditions and outperforming Pd(OAc)2 (ESI, Figure S8A). Although shorter hydrophobic spacers 
seemed to be preferred in PBS (8 > 9 > 10), clear structure–activity relationships could not be 
established for the catalytic activity, particularly in the cell lysate, highlighting the need for methods 
to rapidly generate combinatorial catalyst libraries. 
Catalyst 8 was further evaluated by monitoring the decaging of DCF-1 (50 µM) by HPLC, with the 
experiments performed in PBS and in human plasma to mirror a cellular environment rich in 
proteins. In PBS, 8 (2 mol%) gave 92% conversion to DCF-2 after 5 h (Figure 2C), whereas in plasma 
97% conversion was observed (ESI, Figure S8B).   
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 Figure 2. (A) Pd catalysed depropargylation reaction of profluorophore DCF-1 to give fluorescent DCF-2 (λEx/Em 480/520 nm). (B) Screening of catalysts 5–12 (0.8 mol%) for 
the activation of DCF-1 (10 µM) in PBS (n = 3). The reactions were monitored over 4 h and the increase in fluorescence recorded over time and compared to blank (no 
catalyst) and 0.8 mol% Pd(OAc)2. (C) The catalytic decaging of DCF-1 (50 µM) with catalyst 8 (2 mol%) monitored by HPLC (detection at 282 nm) over 5 h with the reaction 
carried out in PBS, showing > 92% of DCF-1. 
 
Prodrug activation in cancer cells and in cancer cell spheroids 
The catalyst 8 was evaluated for its efficiency to activate the caged anticancer drug N-propargyl 
protected 5-fluorouracil24 (Pro-5-FU) (Figure 3A). In PBS, 5 mol% of 8 was able to convert Pro-5-FU 
(100 µM) into the active drug 5-fluorouracil (5-FU) within 48 h, as monitored by HPLC (Figure 3B). 
The co-treatment of MCF-7 cell first with Pro-5-FU (100 µM) for 24 h followed by catalyst 8 (10 
mol%) for 4 days resulted in comparable cytotoxicity (MTT assay) to 5-FU (Figure 3C), with the drug 
activation likely taking place both intra- and extracellularly (Pro-5-FU is readily taken up by cells30). 
Catalyst 8 did not show notable cytotoxicity with 84% cell viability at 10 µM concentration. 
Next, MCF-7 spheroids were treated with the prodrug Pro-5-FU (100 µM) and catalyst 8 (10 mol%) 
for 5 days, stained with the LIVE/DEAD™ Cell Imaging Kit (488/570), and analysed by fluorescence 
microscopy. Spheroids treated with both the prodrug and catalyst resulted in cell death comparable 
to cells treated with 5-FU, whereas treatment with only the catalyst or the prodrug Pro-5-FU had 
no effect on the viability of the 3D spheroids (Figure 3D). These results demonstrate that the catalyst 
was able to decage a protected prodrug in a more representative 3D cancer model, which may have 
applications in future anticancer prodrug therapies. 
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Figure 3.  (A) The Pd-catalysed decaging of prodrug 5-fluoro-1-propargyluracil Pro-5-FU into the active anticancer drug 5-fluorouracil 5-FU. (B) Decaging of Pro-5-FU (100 
µM) with catalyst 8 (5 mol %) in PBS (pH 7.4, 37 °C) monitored by HPLC with detection at 282 nm. (C) MTT cytotoxicity assay for prodrug activation in MCF-7 cells. The 
prodrug Pro-5-FU (100 μM with 1% DMSO) did not induce cytotoxicity and the NHC–Pd catalyst 8 (10 µM) only showed minor reduction in cell viability (84% viability) after 
5 days incubation (untreated control cells were defined as 100% viable). Co-treatment with catalyst 8 (10 mol%, 10 µM) and Pro-5-FU (100 µM) for 5 days resulted in 
comparable cytotoxicity to 5-FU. (D) in situ activation of prodrug Pro-5-FU by catalyst 8 in 3D MCF-7 spheroids (drug activation most likely happening extracellularly). The 
spheroids were imaged for live/dead status, Green cells (λEx/Em 495/520 nm) are live whilst the red cells (λEx/Em 595/615 nm) are dead. (i) Untreated spheroid (control); (ii) 
Spheroid treated with (10 µM) of catalyst 8; (iii) Spheroid treated with 5-FU (100 µM) resulting in cell death; (iv) Spheroid treated with prodrug Pro-5-FU (100 µM) showing 
good viability; (v) Spheroid co-treated with the Pro-5-FU (100 µM) and catalyst 8 (10 µM) suggesting cell death equivalent to that seen with 100 µM of 5-FU. Scale bar 100 
μm. 
 
Conclusions 
A highly efficient microwave assisted solid-phase synthesis of NHC–Pd catalysts, based on the ‘sub 
monomer’ approach was developed and used to generate biocompatible catalysts on scale. Catalyst 
8, comprising of the NHC–Pd moiety linked to a glycine, was the most robust catalyst in the series 
and was able to activate a fluorogenic probe in a biological setting and decage the protected 
anticancer drug (5-fluoro-1-propalgyluracil) in a 3D cancer cell culture resulting in comparable cell 
death to 5-fluorouracil. These robust NHC-Pd catalysts have a carboxylic acid that can be readily 
converted to a stable active ester thus providing a handle for bioconjugation and offering 
applications for both specific cell targeting ligands and bioorthogonal prodrug activations. 
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‡  The solid-phase approach used here offers advantages over more traditional solution-phase 
methods, namely the use of mass-action to drive the chemistries and the removal of intermediary 
purification steps. The ligand was previously synthesised in three steps (in solution) with a combined 
reaction time of 7.5 h (compared to 3 h in this work) requiring both silica column chromatography 
and preparative RP-HPLC purification.40 
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